Enigma of a rapid introduction of antiangiogenic therapy with bevacizumab in glioblastoma - A new era in the treatment of malignant brain tumours?

Acta Oncologica

Volumn 48, Issue 1, 2009, Pages 6-8

  Henriksson, Roger ^a   Bergström, Per ^a   Johansson, Mikael ^a   Sandström, Maria ^a  

^a UMEÅ UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CEDIRANIB; CORTICOSTEROID; GADOLINIUM; IRINOTECAN; LOMUSTINE; PROCARBAZINE; TEMOZOLOMIDE; VALGANCICLOVIR; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; VINCRISTINE;

ANTIANGIOGENIC THERAPY; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; DRUG EFFECT; DRUG EFFICACY; EDITORIAL; FATIGUE; GLIOBLASTOMA; HUMAN; NEOVASCULARIZATION (PATHOLOGY); NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBOEMBOLISM; TREATMENT RESPONSE; TUMOR RECURRENCE; WOUND DEHISCENCE;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; BRAIN NEOPLASMS; FEMALE; GLIOBLASTOMA; HUMANS; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC;

EID: 58149085682     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.1080/02841860802468112     Document Type: Editorial

References (14)

1. Miramanoff M. Unpublished data presented at Perspectives in CNS Malignancies IV in Berlin March 28-29, 2008
2. Stark-Vance V. Bevacizumab and CPT-11 in the treatment of relapsed malignant glioma. J Neurooncol 2005;7:369(Abstract 342).
3. Vredenburgh JJ, Desjardins A, Herndon JE, Marcello J, Reardon DA, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007;25:4722-9.
4. Skovgaard-Poulsen H, Grunnet K, Sorensen M, Hasselbach B, Nelausen K, Kosteljanetz M, et al. Adult primary brain tumour patients with a history of multiple recurrences: Results of treatment with an angiogenesis inhibitor, bevacizumab, combined with irinotecan. Acta Oncol (in press).
5. Louis DN, Oghaki H, Wiestler OD, Cavenee WK. WHO classification of tumours in the central nervous system. 2007; IARC.
6. Hicklin DJ, Ellis LM. Role of the VEGFR pathway in tumour growth and angiogenesis. J Clin Oncol 2005;23:1011-27.
7. Johansson M, Brännström T, Bergenheim AT, Henriksson R. Spatial expression of VEGF-A in human glioma. J Neurooncol 2002;59:1-6.
8. Sandström M, Johansson M, Bergström P, Bergenheim AT, Henriksson R Effects of the VEGFR inhibitor ZD6474 in combination with radiotherapy and temozolomide in an orthotopic glioma model. J Neurooncol 2008;88:1-9.
9. Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT. Angiogenesis in brain tumours. Nat Rev Neurosci 2007;8:610-22.
10. Batchelor T, Sorensen G, di Tomaso E, Zhang W-T, Guda D, et al. AZD2171, a pan VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007;11:83-95
11. Sathornsumetee, Cao Y, Marcello JE, Herndon II JE, McLendon RE, Desjardins A. Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. J Clin Oncol 2008;26:271-8.
12. Lai A, Filka E, McGibbon B, Nghiemphu PI, Graham C, Yong W, et al. Phase II pilot study of bevacizumab in combination with temozolomide and radiotherapy for upfront treatment of patients with newly diagnosed glioblastoma multiforme: Interimanalysis of safety and tolerability. Int J Radiat Oncol Biol Phys 2008;71:1372-80.
13. Ananthnarayan S, Bahng J, Roring J, Nghiemphu P, Lai A, et al. Time course of imaging changes of GBM during extended bevacizumab treatment. J Neurooncol 2008.
14. Cloughesy TF, Prados MD, Wen PY, Mikkelsen T, Abrey LE, Schiff D, et al. A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory gliobl astoma (GBM). ASCO 2008, Chigaco. Abstract 2010b.